We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





World’s First Test Kit Detects Omicron Variant by Combining Gene Dropout and Mutations Specific Detection

By LabMedica International staff writers
Posted on 10 Jan 2022

The world’s first test kit that can detect the B. More...

1.1.529 (Omicron) variant by combining S-gene target failure (SGTF) and S-gene mutation amplification (SGMA) promises to cut down procedural delays in genome sequencing to ascertain the latest SARS-CoV-2 variant.

Tata Medical & Diagnostic Centre (Tamil Nadu, India) has developed the first-of-its-kind RT-PCR test kit dubbed OmiSure that can capture both the gene dropout and specific mutation to detect the Omicron variant of COVID-19 on nasal and oral swab samples. The test is compatible with all common Real-Time PCR devices and has been approved by India’s regulatory body, the Indian Council of Medical Research (ICMR). It has been designed to pick up all SARS-CoV-2 variants, but specifically pulls out Omicron. The test takes about 2.5 hours from specimen collection to reporting and can be performed in all RT-PCR labs without the need for any special training.

OmiSure is a real time PCR test and not a home testing kit as it detects viral genetic material and not viral antigen. It is also not a Rapid Antigen Test (RAT) and reportedly requires a certain amount of bio-safety. The single tube, fully multiplexed test comes with two checks in place for Omicron detection and has reported 100% sensitivity and 99.25% specificity for the detection of variants of SARS-CoV-2, including Omicron.

OmiSure can help eliminate the need for genome sequencing to detect Omicron amidst the fresh surge in cases that is exerting pressure on laboratories across the world. The company is also planning to export OmiSure kits and has applied for licensure to the European Union and US Food and Drug Administration (USFDA).

Related Links:
Tata Medical & Diagnostic Centre 


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.